<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Iseppon F</submitter><funding>Cancer Research UK</funding><funding>Versus Arthritis</funding><funding>NIHR Cambridge Biomedical Research Centre</funding><funding>Medical Research Council</funding><funding>UK Research and Innovation Medical Research Council</funding><funding>Wellcome Trust</funding><pagination>100168</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11570969</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>16</volume><pubmed_abstract>Genetic deletion and pharmacological inhibition are distinct approaches to unravelling pain mechanisms, identifying targets and developing new analgesics. Both approaches have been applied to the voltage-gated sodium channels Na&lt;sub>v&lt;/sub>1.7 and Na&lt;sub>v&lt;/sub>1.8. Genetic deletion of Na&lt;sub>v&lt;/sub>1.8 in mice leads to a loss of pain and antagonists are effective analgesics. The situation with Nav1.7 is more complex. Complete embryonic loss of Na&lt;sub>v&lt;/sub>1.7 in humans or in mouse sensory neurons leads to anosmia as well as profound analgesia as a result of diminished neurotransmitter release. This is mediated by enhanced endogenous opioid signaling in humans and mice. In contrast, anosmia is opioid-independent. Sensory neuron excitability and autonomic function appear to be normal. Adu</pubmed_abstract><journal>Neurobiology of pain (Cambridge, Mass.)</journal><pubmed_title>Sodium channels Na&amp;lt;sub&amp;gt;v&amp;lt;/sub&amp;gt;1.7, Na&amp;lt;sub&amp;gt;v&amp;lt;/sub&amp;gt;1.8 and pain; two distinct mechanisms for Na&amp;lt;sub&amp;gt;v&amp;lt;/sub&amp;gt;1.7 null analgesia.</pubmed_title><pmcid>PMC11570969</pmcid><funding_grant_id>21950</funding_grant_id><funding_grant_id>221521/Z/20/Z</funding_grant_id><funding_grant_id>185341</funding_grant_id><funding_grant_id>571476</funding_grant_id><funding_grant_id>MR/V012509/1</funding_grant_id><pubmed_authors>Kanellopoulos AH</pubmed_authors><pubmed_authors>Wood JN</pubmed_authors><pubmed_authors>Woods CG</pubmed_authors><pubmed_authors>Caan G</pubmed_authors><pubmed_authors>Thalassinos K</pubmed_authors><pubmed_authors>Cubuk C</pubmed_authors><pubmed_authors>Lewis MJ</pubmed_authors><pubmed_authors>Cox JJ</pubmed_authors><pubmed_authors>Chiozzi R</pubmed_authors><pubmed_authors>Tian N</pubmed_authors><pubmed_authors>Iseppon F</pubmed_authors><pubmed_authors>Zhao J</pubmed_authors><pubmed_authors>Zhou J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Sodium channels Na&amp;lt;sub&amp;gt;v&amp;lt;/sub&amp;gt;1.7, Na&amp;lt;sub&amp;gt;v&amp;lt;/sub&amp;gt;1.8 and pain; two distinct mechanisms for Na&amp;lt;sub&amp;gt;v&amp;lt;/sub&amp;gt;1.7 null analgesia.</name><description>Genetic deletion and pharmacological inhibition are distinct approaches to unravelling pain mechanisms, identifying targets and developing new analgesics. Both approaches have been applied to the voltage-gated sodium channels Na&lt;sub>v&lt;/sub>1.7 and Na&lt;sub>v&lt;/sub>1.8. Genetic deletion of Na&lt;sub>v&lt;/sub>1.8 in mice leads to a loss of pain and antagonists are effective analgesics. The situation with Nav1.7 is more complex. Complete embryonic loss of Na&lt;sub>v&lt;/sub>1.7 in humans or in mouse sensory neurons leads to anosmia as well as profound analgesia as a result of diminished neurotransmitter release. This is mediated by enhanced endogenous opioid signaling in humans and mice. In contrast, anosmia is opioid-independent. Sensory neuron excitability and autonomic function appear to be normal. Adu</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Jul-Dec</publication><modification>2026-05-26T20:11:34.978Z</modification><creation>2025-04-21T21:43:10.034Z</creation></dates><accession>S-EPMC11570969</accession><cross_references><pubmed>39559752</pubmed><doi>10.1016/j.ynpai.2024.100168</doi></cross_references></HashMap>